SCHEMBL2065716

SCHEMBL2065716

O=C1C=Nc2cccnc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100A4 P26447 7/20 0.45
CDC25B P30305 3/20 0.45
TDP2 O95551 3/20 0.45
NSD2 O96028 3/20 0.45
PAX8 Q06710 3/20 0.45
TDP1 Q9NUW8 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ABL1 P00519 1/20 0.45
PLCG1 P19174 1/20 0.45
CES1 P23141 1/20 0.45
RIN1 Q13671 1/20 0.45
THRB P10828 1/20 0.45
BLM P54132 1/20 0.45
GAA P10253 1/20 0.45
PTPRC P08575 2/20 0.41
CTSL P07711 1/20 0.41
CTSS P25774 1/20 0.41
PTPN13 Q12923 1/20 0.41
PADI1 Q9ULC6 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10434479 0.88 TDP2 (0.47) S100A4CDC25BTDP2NSD2PAX8
SCHEMBL836285 0.71 S100A4 (0.52) S100A4CDC25BTDP2NSD2PAX8
SCHEMBL1020681 0.69 TDP2 (0.41) S100A4CDC25BTDP2NSD2PAX8
SCHEMBL1187365 0.68 TDP1 (0.44) S100A4CDC25BTDP2NSD2PAX8
SCHEMBL1666091 0.67 PDE3B (0.38) S100A4CDC25BTDP2NSD2PAX8
SCHEMBL300666 0.67 TDP2 (0.46) S100A4CDC25BTDP2NSD2PAX8
SCHEMBL7658855 0.66 MAPT (0.50) MEN1KMT2ABLMKDM4EMAPT
Hydrochloric Acid SCHEMBL4046012 0.65 PDE3B (0.37) TDP2NSD2PAX8TDP1MEN1
SCHEMBL987746 0.65 TDP2 (0.41) S100A4CDC25BTDP2NSD2PAX8
SCHEMBL1497963 0.65 CDC25B (0.42) S100A4CDC25BTDP2TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597370-B2 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-03-24 US disclosed
US-20190144403-A1 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-05-16 US disclosed
US-10173991-B2 Sulfone amide linked benzothiazole inhibitors of endothelial lipase BRISTOL-MYERS SQUIBB COMPANY (US) 2019-01-08 US disclosed
WO-2017214005-A1 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2017-12-14 WO disclosed
EP-2847174-B1 PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2017-05-17 EP disclosed
EP-2844643-B1 PYRIMIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2016-11-30 EP disclosed
EP-2760834-B1 PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2016-11-16 EP disclosed
US-9493412-B2 Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-11-15 US disclosed
US-20160326125-A1 SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2016-11-10 US disclosed
EP-2870153-B1 SULFONYL CONTAINING BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2016-11-02 EP disclosed
US-8148395-B2 Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases SANOFI-AVENTIS (FR) 2012-04-03 US disclosed
WO-2011157827-A1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES SANOFI (FR) 2011-12-22 WO disclosed
CN-101415706-A Azolopyridin-3-one derivatives as inhibitors of endothelial lipase SANOFI AVENTIS (FR) 2009-04-22 CN disclosed
CN-101415706-A Azolopyridin-3-one derivatives as inhibitors of endothelial lipase SANOFI AVENTIS (FR) 2009-04-22 CN disclosed
US-20090054478-A1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES SANOFI-AVENTIS (FR) 2009-02-26 US disclosed
US-20090054478-A1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES SANOFI-AVENTIS (FR) 2009-02-26 US disclosed
EP-2001879-A1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF ENDOTHELIAL LIPASE sanofi-aventis (FR) 2008-12-17 EP disclosed
EP-2001879-A1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF ENDOTHELIAL LIPASE sanofi-aventis (FR) 2008-12-17 EP disclosed
WO-2007110216-A1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF ENDOTHELIAL LIPASE SANOFI-AVENTIS (DE) 2007-10-04 WO disclosed
WO-2007110216-A1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF ENDOTHELIAL LIPASE SANOFI-AVENTIS (DE) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10173991-B2 Sulfone amide linked benzothiazole inhibitors of endothelial lipase LIPG, LIPE, LPL S100A4 3422/4885CDC25B 1763/4885TDP2 1648/4885
US-20090054478-A1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES PNLIP, LPL, CEL S100A4 2645/4885CDC25B 1756/4885TDP2 669/4885
US-20190144403-A1 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS LIPG, LPL, CEL S100A4 3962/4885CDC25B 2349/4885TDP2 1043/4885
US-20160326125-A1 SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, LIPE, LPL S100A4 3422/4885CDC25B 1763/4885TDP2 1648/4885
US-10597370-B2 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors LIPG, LPL, CEL S100A4 3962/4885CDC25B 2349/4885TDP2 1043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.